Medicare's bundled payment killed dialysis drug innovation

Since CMS implemented the ESRD bundled payment system in 2011, rolling all dialysis drugs and biologics into a single per-treatment payment, pharmaceutical innovation for dialysis patients has effectively stopped. Currently, clinicaltrials.gov lists only two phase 3 registrational trials in the ESRD space, compared to robust pipelines in cancer and cardiology. Medicare has approved coverage for just four new ESRD drugs since the bundle began, half of which are no longer widely available. The human cost is concrete: when a temporary add-on payment (TDAPA) existed for Parsabiv (a drug for secondary hyperparathyroidism), 14.2% of dialysis patients received it monthly. After the TDAPA expired in January 2021, usage collapsed to 0.7% -- not because the drug stopped working, but because clinics lost money dispensing it within the fixed bundle. Similarly, CKD-associated pruritus (severe itching) affects 16% of dialysis patients, but less than 1% have access to the approved treatment because the bundle makes it unprofitable to provide. The structural reason: under the bundle, every new drug or device that a clinic adopts comes directly out of its margin. Dialysis providers have zero financial incentive to adopt innovations.